NCT03925662RecruitingPhase 3
Mebendazole as Adjuvant Treatment for Colon Cancer
Clinical Study Evaluating Mebendazole as Adjuvant Therapy in Patients With Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 24 Apr 2019 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
mebendazole treating colon cancer
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 22 Apr 2019
- Start date
- 1 Apr 2019
- Primary completion date
- Dec 2028
- Lead sponsor
- Sherief Abd-Elsalam
- Diseases
- Colorectal cancer
- NCT number
- NCT03925662
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 40
- From 1 Apr 2019 to the primary completion date, Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Allergy to mebendazole.
Other
- Agranulocytosis
- Pregnancy
Who the study is looking for
- Colorectal cancer stage 4.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sherief Abd-Elsalam Coordinator of this site? Confirm its status | Cairo | Egypt | Recruiting |
Related publications
- Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer.Life Sci · 2022 · PMID 35385794
This page is information, not medical advice. Discuss any trial with your doctor.